SecBot SecBot
8-K ·Filed Jul 14, 2026

HCA

HCA Healthcare, Inc.
BEARISH
Impact 6/10
Horizonweeks Processed4mo ago SEC0001193125-26-302539
8-K Item 2.02: Earnings release
Actionable Insight ▼ Bearish

The guidance cut signals worsening payer mix from exchange losses, a structural headwind that may persist through 2026. The full Q2 earnings call on July 24 will provide more detail on volume trends and cost mitigation. Monitor for further deterioration in exchange enrollment and any offset from Medicaid programs.

DirectionBearish
Confidencemedium
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$363.60
T+0 close · Jul 14, 2026 · via day close
Latest settled
+20.78%
T+60 · $439.17
Vs SPY
+17.41%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 14 $363.60entry
  2. T+1 · 4mo ago +4.16%α +3.77% · $378.71
  3. T+5 · 4mo ago +1.88%α +3.17% · $370.42
  4. T+20 · 3mo ago +13.16%α +10.67% · $411.44
  5. T+60 · 6w ago +20.78%α +17.41% · $439.17
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

HCA Healthcare issued preliminary Q2 2026 results and revised 2026 guidance downward. Q2 revenue grew 8.7% YoY to ~$20.23B and EPS rose to $7.62, but a $400M unfavorable payer mix shift from health insurance exchange losses drove a guidance cut: 2026 EPS guidance lowered to $28.70-$30.50 (from $29.10-$31.50) and net income guidance reduced by ~$195M-$335M at the midpoint. The Medicaid Supplemental Payment Programs provided a $400M offset in Q2, but the net outlook is negative.

Key Financial Metrics

Guidance
$77.0B-$79.5B
lowered

Key Facts

  • Preliminary Q2 2026 revenue ~$20.23B (+8.7% YoY), net income ~$1.699B ($7.62 EPS) vs $1.653B ($6.83) in Q2 2025
  • Same facility admissions +2.5%, equivalent admissions +2.7%, ER visits +3.6%
  • Payer mix shift from health insurance exchanges had ~$400M unfavorable impact on Q2 income before taxes
  • Medicaid Supplemental Payment Programs provided ~$400M incremental net benefit in Q2, primarily from Florida
  • 2026 guidance revised: EPS $28.70-$30.50 (from $29.10-$31.50), net income $6.3B-$6.7B (from $6.495B-$7.035B), Adjusted EBITDA $15.4B-$16.1B (from $15.55B-$16.45B)
  • Health Insurance Exchanges assumption worsened to ($1.0B-$1.2B) from ($600M-$900M); Medicaid Supplemental improved to $300M-$500M from ($50M-$250M)
  • Capital expenditure guidance unchanged at $5.0B-$5.5B

Financial Impact

2026 EPS guidance lowered by $0.40-$1.00 per share; net income guidance reduced by ~3-5% at midpoint

revenueepsnet incomeadjusted EBITDA

Risk Factors

  • Further adverse payer mix shifts if exchange enrollment declines continue
  • Potential for additional guidance cuts if surgical volume remains weak
  • Medicaid supplemental payments are subject to regulatory approval and may not recur at same levels

Market Snapshot

Exchange
NYSE
Sector
Services-General Medical & Surgical Hospitals, NEC
Analyst Consensus
63% bullish (30 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001193125-26-302539
Document: hca-20260714.htm0001193125-26-302539
Document: 0001193125-26-302539-index-headers.html0001193125-26-302539
Document: 0001193125-26-302539-index.html0001193125-26-302539
Document: 0001193125-26-302539.txt0001193125-26-302539
8-K Data (Synthetic)0001193125-26-302539

US Market Status

Market Closed · Opens in 7h 33m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 14, 2026